Physician profile
Katrina A Smith
NPI 1104859040
$6,817.65
in general payments reported to CMS, 2019-2025
24 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $49.18 · 2021: $421 · 2022: $967 · 2023: $1,149 · 2024: $1,845 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,121 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,120.99 |
| Education | $259.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,111.56 | 2021-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $968.45 | 2020-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $656.67 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $546.59 | 2021-2025 | Tremfya |
| Amgen INC. | $393.74 | 2024-2025 | Otezla, Tezspire, Otezla |
| Ucb, INC. | $369.94 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $351.69 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $293.98 | 2021-2025 | |
| Leo Pharma INC. | $267.18 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $255.00 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $234.80 | 2023-2025 | Sotyktu |
| Pfizer INC. | $197.44 | 2021-2024 | |
| Dermavant Sciences, INC. | $192.27 | 2022-2024 | Vtama |
| Incyte Corporation | $188.81 | 2022-2024 | Opzelura |
| Medline Industries LP | $182.97 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $120.71 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $116.21 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.94 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.46 | 2022-2024 | Arazlo, Jublia, Siliq |
| Janssen Scientific Affairs, LLC | $49.83 | 2022 | |
| Verrica Pharmaceuticals INC. | $41.54 | 2023-2024 | Ycanth |
| Nabriva Therapeutics, Plc | $37.20 | 2022 | |
| Organon LLC | $35.49 | 2025 | Nexplanon, Vtama |
| Krystal Biotech INC | $17.18 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.